The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults as young as 40, backed by peer-reviewed data on its diagnostic accuracy against amyloid PET imaging.
#Biotech #Biotechnology #FDA #Health #Healthinnovation
Disclaimer: This is NOT a financial advice
The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults as young as 40, backed by peer-reviewed data on its diagnostic accuracy against amyloid PET imaging. #Biotech #Biotechnology #FDA #Health #Healthinnovation Disclaimer: This is NOT a financial advice
0 vue
Publié le 26/08/2026 07:38
The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults as young as 40, backed by peer-reviewed data on its diagnostic accuracy against amyloid PET imaging.
#Biotech #Biotechnology #FDA #Health #Healthinnovation
Disclaimer: This is NOT a financial advice
0 commentaire
?